Nucleoside analog ARC effect on breast cancer cell line
Summary:
Analysis of MCF-7 breast cancer cells treated with the nucleoside analog ARC (NSC 188491). ARC inhibits transcription and selectively kills cancer cells. It has the ability to perturb angiogenesis in vitro. Results provide further insight into the mechanism of action of ARC.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Stockwin LH, Yu SX, Stotler H, Hollingshead MG et al. ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 2009 Feb 20;9:63. PMID: 19232100
